Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 7Terminated 5Recruiting 2Withdrawn 1Unknown 1Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma 1

Interventions

Dexamethasone 3venetoclax 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2calaspargase pegol 2auricularum 2Vincristine 2Thioguanine 2Specimen Handling 2Methotrexate 2Mercaptopurine 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Daunorubicin 2Cytarabine 2Cyclophosphamide 2Calcium Dobesilate 2Bortezomib 2Biopsy 2Asparaginase 2revumenib 1prednylidene 1pegaspargase 1nelarabine 1exifone 1deltacortene 1capivasertib 1blinatumomab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × nelarabine × Clear all
NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡